LOR-2040 is an RNA-targeted drug that specifically targets the R2 component of ribonucleotide reductase, which is required for DNA synthesis and cell proliferation.
The patent covers methods of treating AML patients with LOR-2040 in combination with cytarabine.
LOR-2040 has shown clinical efficacy in Phase I and II clinical trials in relapsed and refractory AML.
Lorus president and CEO Aiping Young said this patent should be useful in their partnership discussions that are aimed towards advancing clinical development of this drug in this indication.